Key points are not available for this paper at this time.
The clinical candidate alpibectir augments the activity of, and overcomes resistance to, the anti-TB drug ethionamide in vitro and in vivo.
Share your take
Add a clinician perspective alongside expert commentary.
Pieren et al. (2024) studied this question.